Results 71 to 80 of about 5,926 (192)

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, Volume 13, Issue 35, 24 June 2026.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Supplementary Video – Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer:TALAPRO-2 phase III study design

, 2022
VJBM video: Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer:TALAPRO-2 phase III study design 
Xun Lin (11291684), Neeraj Agarwal (53040), Karim Fizazi (40729), Figshare Future Science Group (6457551), Joan Carles (514163), Arun Azad (436362), Mohamed Elmeliegy (12002334), Maria Luisa Paccagnella (12002325), Akos Czibere (81561), Lawrence Ivan Karsh (12002322), Neal D Shore (12434903), Andre P Fay (12434904), Nicola Di Santo (12002331), Curtis Dunshee (12002319)   +13 more
core   +1 more source

Supplementary figure 1.pdf: A Phase I trial of talazoparib in patients with advanced hematologic malignancies

, 2021
Supplementary Figure 1. Dose linearity and proportionality in plasma following multiple doses of talazoparib.
Adrian Bloor (3520115), Ajay K Gopal (11598880), Mark Juckett (11598895), Ying Chen (9697), Rakesh Popat (8859863), Terry Gaymes (11598889), Tobias Menne (11598886), Ryan J Mattison (11598883), Asim Khwaja (11598892), Matthew J Cotter (11598898), Ghulam J Mufti (9332201)   +10 more
core   +1 more source

Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US

Scientific Reports
Breast cancer is one of the tumors with the highest prevalence rate among women in the world, and its BRCA1/2 gene is a common mutation site. Talazoparib, as a targeted PARP inhibitor, can effectively control the occurrence and development of breast ...
Junjie Pan, Ning Ren, Lanqi Ren, YiBei Yang, Qiaoping Xu   +4 more
doaj   +1 more source

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

npj Breast Cancer, 2022
Germline mutations in BRCA1 or BRCA2 exist in ~2–7% of breast cancer patients, which has led to the approval of PARP inhibitors in the advanced setting.
Xuan Liu, Zhongqi Ge, Fei Yang, Alejandro Contreras, Sanghoon Lee, Jason B. White, Yiling Lu, Marilyne Labrie, Banu K. Arun, Stacy L. Moulder, Gordon B. Mills, Helen Piwnica-Worms, Jennifer K. Litton, Jeffrey T. Chang   +13 more
doaj   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

Human Absorption, Metabolism, and Excretion (hAME) Mass Balance Studies in Patients With Cancer

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Radiolabeled mass balance human studies are a critical component of clinical pharmacology programs supporting the development of new investigational drugs. These studies provide information about absorption, metabolism, and excretion (AME) of the parent drug and metabolite(s) in the human body and are normally conducted in healthy volunteers ...
Begoña de las Heras, Claudine Oelke, Pamela Atwell, Hector Herrero, Paulo Nunes, Kamal S. Saini, Laura Vidal Boixader, Catherine Laing, James Bush, Emiliano Calvo   +9 more
wiley   +1 more source

Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation

, 2022
PURPOSE: The immunological profile of early-stage breast cancer treated with neoadjuvant PARP inhibitors has not been described. The aim of this study was to delineate the changes in the tumor immune microenvironment (TiME) induced by talazoparib ...
Scoggins, Marion E, Garber, Haven, Lu, Yiling, Chang, Jeffrey T, Contreras, Alejandro, Whitman, Gary J, Kumar, Tapsi, Cuentas, Edwin Roger Parra, Hobbs, Evie, Adrada, Beatriz E, Litton, Jennifer K, Mittendorf, Elizabeth A, Yang, Fei, Lee, Sanghoon, Arun, Banu K   +14 more
core   +1 more source

Real‐world prevalence of PD‐L1 positivity in early‐stage/metastatic triple‐negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study

Histopathology, Volume 88, Issue 7, Page 1373-1384, June 2026.
In the real‐world VANESSA study in triple‐negative breast cancer, PD‐L1‐positive prevalence was 38% in early‐stage and 20% in metastatic tumours, lower than in prospective trials. The lower prevalence in smaller versus larger tissue samples and by local versus central assessment underlines the importance of robust PD‐L1 testing to determine eligibility
Corrado D'Arrigo, Sitki Tuzlali, Romualdo Barroso‐Sousa, Nagi S El Saghir, Rebecca Dent, Nataša Medić‐Milijić, Gyungyub Gong, Shahin Sayed, Tu Thai Anh, Alisan Zirtiloglu, Götz Hartleben, Paula Toro, Iman Estaytieh, Enya Weber, Regula Deurloo, João Mouta, Lazar Popovic   +16 more
wiley   +1 more source

Olaparib‐associated cutaneous vasculitis in a patient with breast cancer

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marcial Álvarez‐Salafranca, Teresa Puértolas, Adrián Diago, María Carmen Gómez‐Mateo   +3 more
wiley   +1 more source